Rhythm Pharmaceuticals (NASDAQ:RYTM) has accomplished a significant milestone in its journey towards combating obesity. The company has wrapped up the screening for Phase 3 enrollment of its anti-obesity drug candidate setmelanotide. The eagerly anticipated topline data is projected to be unveiled in the first half of 2025.

Setmelanotide, the focal point of Rhythm’s research, is being evaluated for its potential to address acquired hypothalamic obesity – a disorder that has long eluded the medical community.

Laying the foundation for future breakthroughs, Rhythm has received the green light from the FDA to initiate clinical testing of its drug candidate RM-718. This visionary step is anticipated to kick off in the first half of 2024 and promises to provide invaluable insights into the treatment of patients grappling with hypothalamic obesity.

Moreover, the company has garnered approval from Spanish healthcare authorities regarding the reimbursement for setmelanotide. The approval extends to the treatment of obesity and hunger associated with Bardet-Biedl syndrome and POMC/LEPR deficiencies, underscoring Rhythm’s commitment to addressing a myriad of obesity-related challenges.

Unveiling yet another layer of its strategic ambition, Rhythm has announced the acquisition of the global rights to a Phase 2 anti-obesity compound developed by South Korea’s LG Chem. This strategic move further amplifies the company’s position at the forefront of innovative anti-obesity research and development.